These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10653454)

  • 1. Cost-effectiveness of screening patients for hepatitis C.
    Gordon FD
    Am J Med; 1999 Dec; 107(6B):36S-40S. PubMed ID: 10653454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
    Jülicher P; Chulanov VP; Pimenov NN; Chirkova E; Yankina A; Galli C
    PLoS One; 2019; 14(7):e0219687. PubMed ID: 31310636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for Hepatitis C in injecting drug users: a cost utility analysis.
    Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
    J Public Health (Oxf); 2004 Mar; 26(1):61-71. PubMed ID: 15044577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P; Galli C
    J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of EGCRISC application versus hepatitis C virus mass screening in Egypt.
    El-Ghitany EM
    J Infect Public Health; 2019; 12(3):442-444. PubMed ID: 30220579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.
    Nakamura J; Terajima K; Aoyagi Y; Akazawa K
    Tohoku J Exp Med; 2008 May; 215(1):33-42. PubMed ID: 18509233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
    Morris MD; Brown B; Allen SA
    Int J Prison Health; 2017 Sep; 13(3-4):192-199. PubMed ID: 28914118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
    Leal P; Stein K; Rosenberg W
    J Med Screen; 1999; 6(3):124-31. PubMed ID: 10572842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of targeted screening for hepatitis C in The Netherlands.
    Helsper CW; Borkent-Raven BA; de Wit NJ; van Essen GA; Bonten MJ; Hoepelman AI; Janssen MP; de Wit GA
    Epidemiol Infect; 2012 Jan; 140(1):58-69. PubMed ID: 21324216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening blood donations for hepatitis C in Central Africa: analysis of a risk- and cost-based decision tree.
    Cancré N; Bois F; Grésenguet G; Fretz C; Fournel JJ; Bélec L
    Med Decis Making; 1999; 19(3):296-306. PubMed ID: 10424836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of screening for hepatitis C virus infection based on risk factors.
    Mallette C; Flynn MA; Promrat K
    Am J Gastroenterol; 2008 Jan; 103(1):131-7. PubMed ID: 17894850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
    Coward S; Leggett L; Kaplan GG; Clement F
    BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.